A phase I/II study of intravenous doxil [doxorubicin liposomal] and intraperitoneal carboplatin as salvage therapy in patients with recurrent ovarian cancer.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2017 Biomarkers information updated
- 25 Mar 2009 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 25 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.